Cancer News and Research

Latest Cancer News and Research

$Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010$

Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010

Genmab A/S announced today that data from the pivotal trial of zalutumumab in refractory head and neck cancer patients will be presented today at the 2010 American Society of Clinical Oncology Annual Meeting, which will be held June 1-8 in Chicago, Illinois. This is the first controlled study to demonstrate that an EGFr-targeted antibody given as monotherapy induces a clinically meaningful improvement in progression free survival in patients with refractory head and neck cancer who have failed platinum-based chemotherapy.

9 Jun 2010

Blood vessel-blocking drug slows prostate cancer progression: Experts

A blood vessel-blocking drug called tasquinimod slowed the rate of disease progression in a clinical trial of 200 prostate cancer patients, according to experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University.

9 Jun 2010

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.

9 Jun 2010

Clinical results from the use of hyperthermia to treat cervical cancer presented at ESHO meeting

BSD Medical Corporation today reported significant clinical results from the use of hyperthermia to treat cervical cancer. The results were presented at the annual meeting of the European Society for Hyperthermic Oncology, which was held in Rotterdam, The Netherlands, on May 19 to 21, 2010.

9 Jun 2010

GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting

GE Healthcare, a unit of the General Electric Company, today will present results of a phase 1 study of anti-[18F]FACBC at the 57th annual meeting of the Society of Nuclear Medicine in Salt Lake City, Utah. The presentation closely follows the launch of the phase 2 clinical development program for anti-[18F]FACBC, which was initially discovered and developed by Emory University, Atlanta, Georgia, and was licensed to Nihon Medi-Physics Co., Ltd. (NMP) of Japan.

9 Jun 2010

VARI researchers identify enzyme that could help diagnose and treat cholangiocarcinoma

In collaboration with the National Cancer Centre, Singapore, Van Andel Research Institute researchers have identified an enzyme that could help diagnose and treat cholangiocarcinoma, a form of liver cancer that strikes up to 3,000 new patients each year in the United States.

9 Jun 2010

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax today announced approval by the Norwegian Medicines Agency ('Statens Legemiddelverk') to test a combination of LTX-315 and GV1001 as vaccine therapy in patients with resected tumours. Lytix Biopharma CEO Gunnar Salid states, "We are delighted to announce the approval of our joint study to test a combination of two very interesting experimental drugs.

9 Jun 2010

Helix BioPharma reports Phase II clinical results of Topical Interferon Alpha-2b for ano-genital warts

Helix BioPharma Corp. today announced results from the Phase II clinical trial assessing the efficacy and safety of Topical Interferon Alpha-2b cream for the treatment of ano-genital warts (AGW).

9 Jun 2010

Harvard and University of Montreal researchers challenge views on how cells respond to stimuli

People have them, cats have them and whales have some, too. Neurons, those interlinked nerve cells that carry sensations including pain, stretch from our spinal cords to the tips of our toes, paws or fins. According to a new study published in the journal Cell, scientists from the Harvard Medical School, the University of Montreal and the Dana-Farber Cancer Institute have found a new way by which nerve cells relay information that tell them to grow from millimeters to meters in length.

9 Jun 2010

Experimental drug ipilimumab increases overall survival in patients with metastatic melanoma: Study

The Melanoma Network of Canada is excited with the new hope that long-anticipated results of a late-stage skin cancer trial brings to patients with advanced melanoma. The results, presented at the American Society of Clinical Oncology annual meeting, show increased survival with the experimental treatment ipilimumab in patients with previously-treated metastatic melanoma, the most deadly form of skin cancer.

9 Jun 2010

LAB Research completes exclusive radiotherapy partnership with DMV

LAB Research Inc., a Canadian-based global non-clinical contract research organization, today announced that it has completed an exclusive radiotherapy partnership with DMV Veterinary Centre creating a dedicated research platform.

9 Jun 2010

Psychological intervention program teaches breast cancer patients how to cope with the disease

A psychological intervention program designed for breast cancer patients reduces the risk of dying if the cancer recurs, new research shows. The study is the latest in a series at Ohio State University that have shown that an intervention program that teaches patients how to cope with the disease can boost their health, well-being and even their chances of survival.

9 Jun 2010

PharmaMar commences Aplidin Phase III registration trial for multiple myeloma

PharmaMar SA today announced that a registration trial in relapsed/refractory multiple myeloma patients has been initiated with Aplidin(R) (plitidepsin) in combination with dexamethasone versus dexamethasone alone.

9 Jun 2010

TransTech Pharma, Forest Laboratories Holdings agree to develop and commercialize GKA compounds

TransTech Pharma, Inc and Forest Laboratories, Inc., today announced that TransTech Pharma and Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. have entered into a license agreement for the development and commercialization of small molecule compounds discovered and developed by TransTech Pharma.

9 Jun 2010

Researchers look at exercise as new way to slow degenerative processes of ALS

University of Alberta researchers are looking at exercise as a new way to slow the degenerative processes of ALS, commonly known as Lou Gehrig's disease. Dr. Kelvin Jones, a recipient of this year's ALS Canada Discovery Grant, has been pioneering research in this field for four years, using mice genetically altered to present familial ALS. He's found that exercise has a positive impact on the mice, slowing the disease significantly.

9 Jun 2010

Endo, Penwest announce settlement of OPANA ER litigation with Impax

Endo Pharmaceuticals and Penwest Pharmaceuticals announced today that the companies have settled litigation with Impax Laboratories, Inc. regarding the production and sale of generic formulations of OPANA® ER (oxymorphone hydrochloride) Extended Release tablets.

9 Jun 2010

CPRIT presents a $300,000 check to UNT Health Science Center for cancer research

The Cancer Prevention and Research Institute of Texas recently presented a $300,000 check to the University of North Texas Health Science Center. The check was accepted by the UNT Health Science Center Provost Thomas Yorio, Ph.D., and Richard Kurz, Ph.D., dean of the School of Public Health.

9 Jun 2010

Waste incinerator spewing chemical waste: Says worried Brisbane Lord Mayor

A council commissioned study into the Ace Waste incinerator at Willawong showed that the residents and businesses around the facility were at potential risk of exposure to chemical emissions. The incinerator at Willawong is used to dispose of medical and chemical pollutants that can cause cancer when people are exposed to high concentrations. Brisbane Lord Mayor Campbell Newman revealed this last night. Premier Anna Bligh however denies that there is such a risk. She has assured that the incinerator is safe and there have been no problems for the past twenty year.

8 Jun 2010

Argos presents positive AGS-003 Phase 2 data for newly diagnosed advanced renal cell carcinoma at ASCO

Argos Therapeutics today announced the presentation of positive interim data from a Phase 2 trial that evaluated the clinical activity, safety and immune response of AGS-003 treatment, given in combination with sunitinib, in patients with newly diagnosed advanced renal cell carcinoma (RCC). The data were discussed June 7 in a poster session at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.

8 Jun 2010

Immunomedics reports encouraging results from TF2 Phase I studies for colorectal cancer

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that TF2, a proprietary bispecific antibody, has shown selective tumor localization and minimal normal tissue retention in two early Phase I studies in patients with colorectal cancer.

8 Jun 2010

Cancer News and Research

Latest Cancer News and Research

Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010

Blood vessel-blocking drug slows prostate cancer progression: Experts

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

Clinical results from the use of hyperthermia to treat cervical cancer presented at ESHO meeting

GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting

VARI researchers identify enzyme that could help diagnose and treat cholangiocarcinoma

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

Helix BioPharma reports Phase II clinical results of Topical Interferon Alpha-2b for ano-genital warts

Harvard and University of Montreal researchers challenge views on how cells respond to stimuli

Experimental drug ipilimumab increases overall survival in patients with metastatic melanoma: Study

LAB Research completes exclusive radiotherapy partnership with DMV

Psychological intervention program teaches breast cancer patients how to cope with the disease

PharmaMar commences Aplidin Phase III registration trial for multiple myeloma

TransTech Pharma, Forest Laboratories Holdings agree to develop and commercialize GKA compounds

Researchers look at exercise as new way to slow degenerative processes of ALS

Endo, Penwest announce settlement of OPANA ER litigation with Impax

CPRIT presents a $300,000 check to UNT Health Science Center for cancer research

Waste incinerator spewing chemical waste: Says worried Brisbane Lord Mayor

Argos presents positive AGS-003 Phase 2 data for newly diagnosed advanced renal cell carcinoma at ASCO

Immunomedics reports encouraging results from TF2 Phase I studies for colorectal cancer

Understanding the DNA Damage Response in Innate Immunity eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Newsletters you may be interested in